240 related articles for article (PubMed ID: 34428101)
21. Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial.
Kiyota N; Tahara M; Robinson B; Schlumberger M; Sherman SI; Leboulleux S; Lee EK; Suzuki T; Ren M; Fushimi K; Wirth LJ
Cancer; 2022 Jun; 128(12):2281-2287. PubMed ID: 35380178
[TBL] [Abstract][Full Text] [Related]
22. Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit.
Wirth LJ; Durante C; Topliss DJ; Winquist E; Robenshtok E; Iwasaki H; Luster M; Elisei R; Leboulleux S; Tahara M
Oncologist; 2022 Jul; 27(7):565-572. PubMed ID: 35482606
[TBL] [Abstract][Full Text] [Related]
23. Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy.
Locati LD; Piovesan A; Durante C; Bregni M; Castagna MG; Zovato S; Giusti M; Ibrahim T; Puxeddu E; Fedele G; Pellegriti G; Rinaldi G; Giuffrida D; Verderame F; Bertolini F; Bergamini C; Nervo A; Grani G; Rizzati S; Morelli S; Puliafito I; Elisei R
Eur J Cancer; 2019 Sep; 118():35-40. PubMed ID: 31299580
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological and clinical profile of lenvatinib (E-7080) in the treatment of advanced, radioiodine-refractory, differentiated thyroid cancer.
Hegazi M; Azadi A; Jain D; Redman R; Perez CA
Drugs Today (Barc); 2015 Dec; 51(12):689-94. PubMed ID: 26798849
[TBL] [Abstract][Full Text] [Related]
25. A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer.
Brose MS; Panaseykin Y; Konda B; de la Fouchardiere C; Hughes BGM; Gianoukakis AG; Joo Park Y; Romanov I; Krzyzanowska MK; Leboulleux S; Binder TA; Dutcus C; Xie R; Taylor MH
J Clin Endocrinol Metab; 2022 Feb; 107(3):776-787. PubMed ID: 34664662
[TBL] [Abstract][Full Text] [Related]
26. Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer.
Herranz UA
Cancer Med; 2022 Oct; 11 Suppl 1(Suppl 1):47-53. PubMed ID: 36202606
[TBL] [Abstract][Full Text] [Related]
27. OPTIMIZING LENVATINIB THERAPY IN PATIENTS WITH METASTATIC RADIOACTIVE IODINE-RESISTANT DIFFERENTIATED THYROID CANCERS.
Jasim S; Iniguez-Ariza NM; Hilger CR; Chintakuntlawar AV; Ryder MM; Morris JC; Bible KC
Endocr Pract; 2017 Oct; 23(10):1254-1261. PubMed ID: 28816536
[TBL] [Abstract][Full Text] [Related]
28. Successful recovery from a subclavicular ulcer caused by lenvatinib for thyroid cancer: a case report.
Kitamura M; Hayashi T; Suzuki C; Hirano S; Tateya I; Kishimoto Y; Omori K
World J Surg Oncol; 2017 Jan; 15(1):24. PubMed ID: 28088233
[TBL] [Abstract][Full Text] [Related]
29. Questions and Controversies in the Clinical Application of Tyrosine Kinase Inhibitors to Treat Patients with Radioiodine-Refractory Differentiated Thyroid Carcinoma: Expert Perspectives.
Verburg FA; Amthauer H; Binse I; Brink I; Buck A; Darr A; Dierks C; Koch C; König U; Kreissl MC; Luster M; Reuter C; Scheidhauer K; Willenberg HS; Zielke A; Schott M
Horm Metab Res; 2021 Mar; 53(3):149-160. PubMed ID: 33652491
[TBL] [Abstract][Full Text] [Related]
30. Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study.
Oh HS; Shin DY; Kim M; Park SY; Kim TH; Kim BH; Kim EY; Kim WB; Chung JH; Shong YK; Lim DJ; Kim WG
Thyroid; 2019 Dec; 29(12):1804-1810. PubMed ID: 31592739
[No Abstract] [Full Text] [Related]
31. Long-term efficacy of lenvatinib for recurrent papillary thyroid carcinoma after multimodal treatment and management of complications: a case report.
Tori M; Shimo T
BMC Cancer; 2018 Jun; 18(1):698. PubMed ID: 29954369
[TBL] [Abstract][Full Text] [Related]
32. Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.
Gallo M; Michelon F; Castiglione A; Felicetti F; Viansone AA; Nervo A; Zichi C; Ciccone G; Piovesan A; Arvat E
Endocrine; 2015 Aug; 49(3):726-34. PubMed ID: 25414068
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Limitations of Lenvatinib Therapy for Radioiodine-Refractory Differentiated Thyroid Cancer: Real-World Experiences.
Masaki C; Sugino K; Saito N; Akaishi J; Hames KY; Tomoda C; Suzuki A; Matsuzu K; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Ito K
Thyroid; 2020 Feb; 30(2):214-221. PubMed ID: 31854270
[No Abstract] [Full Text] [Related]
34. Use of multikinase inhibitors/lenvatinib concomitant with locoregional therapies for the treatment of radioiodine-refractory differentiated thyroid cancer.
Berciano-Guerrero MÁ
Cancer Med; 2022 Oct; 11 Suppl 1(Suppl 1):40-46. PubMed ID: 36202609
[TBL] [Abstract][Full Text] [Related]
35. Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.
Wilson L; Huang W; Chen L; Ting J; Cao V
Thyroid; 2017 Aug; 27(8):1043-1052. PubMed ID: 28486081
[TBL] [Abstract][Full Text] [Related]
36. The discovery and development of sorafenib for the treatment of thyroid cancer.
White PT; Cohen MS
Expert Opin Drug Discov; 2015 Apr; 10(4):427-39. PubMed ID: 25662396
[TBL] [Abstract][Full Text] [Related]
37. Clinical factors related to the efficacy of tyrosine kinase inhibitor therapy in radioactive iodine refractory recurrent differentiated thyroid cancer patients.
Sugino K; Nagahama M; Kitagawa W; Ohkuwa K; Uruno T; Matsuzu K; Suzuki A; Masaki C; Akaishi J; Hames KY; Tomoda C; Ogimi Y; Ito K
Endocr J; 2018 Mar; 65(3):299-306. PubMed ID: 29269689
[TBL] [Abstract][Full Text] [Related]
38. Combination therapy with lenvatinib and radiation significantly inhibits thyroid cancer growth by uptake of tyrosine kinase inhibitor.
Suzuki K; Iwai H; Utsunomiya K; Kono Y; Kobayashi Y; Van Bui D; Sawada S; Yun Y; Mitani A; Kondo N; Katano T; Tanigawa N; Akama T; Kanda A
Exp Cell Res; 2021 Jan; 398(1):112390. PubMed ID: 33227314
[TBL] [Abstract][Full Text] [Related]
39. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
Takahashi S; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Fukuda N; Sasaki T; Suzuki T; Ikezawa H; Dutcus CE; Tahara M
Future Oncol; 2019 Mar; 15(7):717-726. PubMed ID: 30638399
[TBL] [Abstract][Full Text] [Related]
40. Lenvatinib complementary with radioiodine therapy for patients with advanced differentiated thyroid carcinoma: case reports and literature review.
Sheu NW; Jiang HJ; Wu CW; Chiang FY; Chiou HC; Hsiao PJ
World J Surg Oncol; 2019 May; 17(1):84. PubMed ID: 31103041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]